BioSpace News Archive

Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under treated health problems, announced that it has been granted a patent from the United States Patent and Trademark Office (USPTO) for the use of its proprietary MEAI as an alcoholic beverage substitute.

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it has entered into a distribution agreement with WEP Clinical Ltd. (“WEP”) in connection with an early access program for DANYELZA (naxitamab-gqgk) 40mg/10mL Injection in Europe.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on January 9, 2023, at 8:30 a.m. ET, it will present topline data from the SEQUOIA Phase 2 study evaluating fazirsiran and provide an outline of a Phase 3 study that was co-developed with and will be run by Takeda.

InflaRx will provide access to certain clinical, manufacturing and regulatory documentation for vilobelimab to facilitate STS’s regulatory filings in China STS plans to request regulatory approval in China for its own anti-C5a-antibody BDB-001 for the treatment of COVID-19 based on InflaRx’s technology in-licensed by STS.

Zymeworks Inc. today announced that management will participate in an upcoming investor conference.

Ad hoc announcement pursuant to Art. 53 LR – Achiko AG is pleased to provide updates on test performance, production and sales.

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it has achieved the target enrollment of approximately 3,000 participants in the groundbreaking Phase 2 PENINSULA trial evaluating VIR-2482 for the prevention of illness due to influenza A.

Akadeum Life Sciences, Inc. , a global leader in buoyancy-based cell separation technology, announces their Microbubble Leukopak Human T Cell Isolation research-use-only kit that resulted from successful external user data with early adopters.

ProSomnus, Inc. today announced full enrollment in the First Line Obstructive Sleep Apnea Treatment study (FLOSAT). FLOSAT is a prospective, independent, head-to-head, crossover study comparing the effectiveness of precision oral appliance therapy (OAT) as first-line treatment versus continuous positive airway pressure (CPAP) therapy.

Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that EPI Health, LLC, a fully consolidated subsidiary of Novan, has entered into an exclusive license agreement with Sato Pharmaceutical Co., Ltd. (“Sato”) granting Sato the right to develop, manufacture and market RHOFADE ® (oxymetazoline hydrochloride 1% cream) for rosacea in Japan.